Beta Bionics, Inc.
Beta Bionics, Inc.（BBNX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BBNX · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
50
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Beta Bionics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BBNX 季度内部人买卖趋势
BBNX 内幕交易卖出 · BBNX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BBNX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BBNX 高管卖出股份 · BBNX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 4, 2026 | Hopman Mark Chief Commercial Officer | Sale | 275 | $3K | Form 4 |
| Jun 4, 2026 | Jones Christy Director | Sale | 2,811 | $39K | Form 4 |
| Jun 2, 2026 | Mensinger Mike Chief Product Officer | Sale | 4,378 | $55K | Form 4 |
| Jun 2, 2026 | Hopman Mark Chief Commercial Officer | Sale | 5,329 | $67K | Form 4 |
| Jun 2, 2026 | Russell Steven Jon Chief Medical Officer | Sale | 4,222 | $53K | Form 4 |
| Jun 2, 2026 | Feider Stephen CFO | Sale | 6,676 | $84K | Form 4 |
| Jun 2, 2026 | Saint Sean President & CEO · Director | Sale | 16,872 | $213K | Form 4 |
| May 21, 2026 | MICHEL GERARD J Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | Jones Christy Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | Jones Christy Director | Sale | 1,998 | $20K | Form 4 |
| May 21, 2026 | Palasis Maria Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | Dearen Danny L. Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | CARNEY SEAN Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | Lezack Adam Director | Award | 16,965 | — | Form 4 |
| May 21, 2026 | Lezack Adam Director | Sale | 1,000 | $10K | Form 4 |
| Dec 2, 2025 | Hopman Mark Chief Commercial Officer | Sale | 856 | $25K | Form 4 |
| Dec 4, 2025 | Hopman Mark Chief Commercial Officer | Sale | 2,061 | $63K | Form 4 |
| Dec 2, 2025 | Russell Steven Jon Chief Medical Officer | Sale | 1,025 | $30K | Form 4 |
| Mar 4, 2026 | Hopman Mark Chief Commercial Officer | Sale | 353 | $4K | Form 4 |
| Feb 27, 2026 | Hopman Mark Chief Commercial Officer | Award | 109,105 | — | Form 4 |
| Mar 2, 2026 | Hopman Mark Chief Commercial Officer | Sale | 834 | $10K | Form 4 |
| Feb 27, 2026 | Russell Steven Jon Chief Medical Officer | Award | 109,105 | — | Form 4 |
| Mar 2, 2026 | Russell Steven Jon Chief Medical Officer | Sale | 1,026 | $13K | Form 4 |
| Feb 27, 2026 | Mensinger Mike Chief Product Officer | Award | 109,105 | — | Form 4 |
| Mar 2, 2026 | Mensinger Mike Chief Product Officer | Sale | 1,064 | $13K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BBNX 内幕交易
BBNX 内幕交易
Beta Bionics, Inc.（BBNX）内幕交易数据来源于公司内部人（包括Feider Stephen (CFO), Hopman Mark (Chief Commercial Officer), Mensinger Mike (Chief Product Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BBNX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Beta Bionics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BBNX 内幕交易 · 5个问题Beta Bionics, Inc.（BBNX）的内部人包括高管和董事，如Feider Stephen (CFO), Hopman Mark (Chief Commercial Officer), Mensinger Mike (Chief Product Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026